Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo

Molecular Therapy Nucleic Acids

Volumn 1, Issue 5, 2012, Pages e19-

  Stedt, Hanna ^a   Alasaarela, Laura ^a   Samaranayake, Haritha ^a,b   Pikkarainen, Jere ^a,b   Määttä, Ann Marie ^b   Kholová, Ivana ^a,c   Parker, Aaron S ^d,e   Ylä Herttuala, Seppo ^a,f  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Finland Ark Therapeutics Oy   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Glioma; Lentivirus; MRI; RNA interference; Src

Indexed keywords

EID: 84868338970     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.13     Document Type: Article

References (46)

1. Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
2. Louis, DN (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1: 97-117.
3. Sathornsumetee, S, Reardon, DA, Desjardins, A, Quinn, JA, Vredenburgh, JJ and Rich, JN (2007). Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24.
4. Rich, JN and Bigner, DD (2004). Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3: 430-446. (Pubitemid 38618125)
5. Pulkkanen, KJ and Yla-Herttuala, S (2005). Gene therapy for malignant glioma: current clinical status. Mol Ther 12: 585-598. (Pubitemid 41350140)
6. Määttä, AM, Samaranayake, H, Pikkarainen, J, Wirth, T and Ylä-Herttuala, S (2009). Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 9: 356-367.
7. Lawler, SE, Peruzzi, PP and Chiocca, EA (2006). Genetic strategies for brain tumor therapy. Cancer Gene Ther 13: 225-233. (Pubitemid 43255759)
8. Olsson, AK, Dimberg, A, Kreuger, J and Claesson-Welsh, L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
9. Park, CM, Park, MJ, Kwak, HJ, Lee, HC, Kim, MS, Lee, SH et al. (2006). Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/ epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66: 8511-8519.
10. Werdich, XQ and Penn, JS (2005). Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. Angiogenesis 8: 315-326.
11. Summy, JM and Gallick, GE (2006). Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12: 1398-1401.
12. Lund, CV, Nguyen, MT, Owens, GC, Pakchoian, AJ, Shaterian, A, Kruse, CA et al. (2006). Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78: 19-29. (Pubitemid 43786654)
13. Criscuoli, ML, Nguyen, M and Eliceiri, BP (2005). Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 105: 1508-1514. (Pubitemid 40223667)
14. Weis, S, Cui, J, Barnes, L and Cheresh, D (2004). Endothelial barrier disruption by VEGFmediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167: 223-229. (Pubitemid 39435066)
15. Singer, O and Verma, IM (2008). Applications of lentiviral vectors for shRNA delivery and transgenesis. Curr Gene Ther 8: 483-488.
16. Consiglio, A, Gritti, A, Dolcetta, D, Follenzi, A, Bordignon, C, Gage, FH et al. (2004). Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc Natl Acad Sci USA 101: 14835-14840. (Pubitemid 39410761)
17. Castanotto, D and Rossi, JJ (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
18. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
19. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
20. Rautsi, O, Lehmusvaara, S, Salonen, T, Häkkinen, K, Sillanpää, M, Hakkarainen, T et al. (2007). Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines. J Gene Med 9: 122-135. (Pubitemid 46444489)
21. Oppermann, H, Levinson, AD, Varmus, HE, Levintow, L and Bishop, JM (1979). Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src). Proc Natl Acad Sci USA 76: 1804-1808.
22. Alvarez, RH, Kantarjian, HM and Cortes, JE (2006). The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929. (Pubitemid 44582963)
23. Yuan, SY (2002). Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 39: 213-223. (Pubitemid 37490747)
24. Gavard, J, Patel, V and Gutkind, JS (2008). Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14: 25-36.
25. (2003). Whither RNAi? Nat Cell Biol 5: 489-490.
26. Bridge, AJ, Pebernard, S, Ducraux, A, Nicoulaz, AL and Iggo, R (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34: 263-264. (Pubitemid 36792856)
27. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
28. Khan, AA, Betel, D, Miller, ML, Sander, C, Leslie, CS and Marks, DS (2009). Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 27: 549-555.
29. Manjunath, N, Wu, H, Subramanya, S and Shankar, P (2009). Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 61: 732-745.
30. Jain, RK, di Tomaso, E, Duda, DG, Loeffler, JS, Sorensen, AG and Batchelor, TT (2007). Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622. (Pubitemid 47093931)
31. Brunton, VG and Frame, MC (2008). Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 8: 427-432.
32. Huang, F, Reeves, K, Han, X, Fairchild, C, Platero, S, Wong, TW et al. (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238. (Pubitemid 46424242)
33. Mäkinen, PI, Koponen, JK, Kärkkäinen, AM, Malm, TM, Pulkkinen, KH, Koistinaho, J et al. (2006). Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 8: 433-441.
34. Sandmair, AM, Turunen, M, Tyynelä, K, Loimas, S, Vainio, P, Vanninen, R et al. (2000). Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther 7: 413-421. (Pubitemid 30210408)
35. Lesch, HP, Laitinen, A, Peixoto, C, Vicente, T, Makkonen, KE, Laitinen, L et al. (2011). Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther 18: 531-538.
36. Yamada, K, McCarty, DM, Madden, VJ and Walsh, CE (2003). Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. BioTechniques 34: 1074-8, 1080.
37. Tyynelä, K, Sandmair, AM, Turunen, M, Vanninen, R, Vainio, P, Kauppinen, R et al. (2002). Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther 9: 917-924. (Pubitemid 35278564)
38. Stripecke, R, Carmen Villacres, M, Skelton, D, Satake, N, Halene, S and Kohn, D (1999). Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6: 1305-1312. (Pubitemid 29359025)
39. Marconi, P, Manservigi, R and Epstein, AL (2010). HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel 13: 169-183.
40. Fan, S, Maguire, CA, Ramirez, SH, Bradel-Tretheway, B, Sapinoro, R, Sui, Z et al. (2005). Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 125: 23-33. (Pubitemid 40298810)
41. Jain, RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62. (Pubitemid 40093472)
42. de Groot, J and Milano, V (2009). Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol 95: 151-163.
43. Ylä-Herttuala, S and Alitalo, K (2003). Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701. (Pubitemid 36749218)
44. Follenzi, A and Naldini, L (2002). HIV-based vectors. Preparation and use. Methods Mol Med 69: 259-274.
45. Laerum, OD, Rajewsky, MF, Schachner, M, Stavrou, D, Haglid, KG and Haugen, A (1977). Phenotypic properties of neoplastic cell lines developed from fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 89: 273-295. (Pubitemid 8154812)
46. Gupta, K, Radotra, BD, Banerjee, AK and Nijhawan, R (2004). Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. Anal Quant Cytol Histol 26: 223-229. (Pubitemid 39100909)